RecruitingNot applicableNCT07270003
A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
Studying Pustulosis palmaris et plantaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xijing Hospital
- Intervention
- Ivarmacitinib(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Xijing hospital, Xi'an, Shaanxi, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07270003 on ClinicalTrials.govOther trials for Pustulosis palmaris et plantaris
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07513142PPP Versus Corticosteroid for Thigh Muscle InjuriesAndrews Research & Education Foundation
- RECRUITINGPHASE4NCT07503652Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar PustulosisFirst Hospital of China Medical University
- RECRUITINGPHASE3NCT07219420A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisUCB Biopharma SRL
- RECRUITINGPHASE2NCT07013201A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar PustulosisLEO Pharma